絞り込み

16525

広告

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).

著者 Danese S , Vermeire S , Hellstern P , Panaccione R , Rogler G , Fraser G , Kohn A , Desreumaux P , Leong RW , Comer GM , Cataldi F , Banerjee A , Maguire MK , Li C , Rath N , Beebe J , Schreiber S
Gut.2017 Dec 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (34view , 0users)

Full Text Sources

Miscellaneous

Other Literature Sources

Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.
PMID: 29247068 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード